The 3D bioprinting market size has grown exponentially in recent years. It will grow from $2.19 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 23%. The growth in the historic period can be attributed to growth in biomedical research funding, rising demand for in vitro drug testing models, early adoption of regenerative medicine, advances in cell culture technologies, increasing use of 3D printing in healthcare.
The 3D bioprinting market size is expected to see exponential growth in the next few years. It will grow to $6.21 billion in 2030 at a compound annual growth rate (CAGR) of 23.2%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing organ transplantation demand, regulatory support for bioprinted tissues, growth in biopharmaceutical research pipelines, advancements in scalable bioprinting platforms. Major trends in the forecast period include tissue engineering for regenerative therapies, patient-specific implant fabrication, advanced bioink formulation development, high-resolution multi-material bioprinting, clinical translation of printed tissues.
The anticipated rise in chronic diseases is set to be a driving factor in the prospective growth of the 3D bioprinting market. Chronic diseases, persisting over extended periods - typically three months or more, and often for a person's lifetime - have increasingly utilized 3D bioprinting for creating tissue models, aiding in chronic disease research and potential organ replacement therapies. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, in 2025, over 35 million new cancer cases are predicted, a 77% increase from the estimated 20 million cases in 2022. Consequently, the upsurge in chronic diseases is a significant driver behind the growth of the 3D bioprinting market.
Major companies in the 3D bioprinting market are focusing on developing innovative technological solutions, such as 3D bioprinters, to improve precision and efficiency in tissue engineering and regenerative medicine. 3D bioprinters are devices that utilize bioinks containing living cells to produce three-dimensional tissue and organ structures for medical research and regenerative medicine applications. For example, in June 2024, Tethon 3D, a US-based developer of ceramic powder and metal-polymer products, introduced the Bison Bio DLP 3D bioprinter, marking its entry into the bioprinting market. Developed in collaboration with Carima, this advanced printer offers adjustable build sizes (30 × 20 mm, 57 × 32 mm, and 96 × 54 mm) and is compatible with Tethon’s proprietary LAP photoinitiator and GelMA hydrogel bioink, crucial for bioprinting living tissues. Measuring 24 × 24 × 24 inches and weighing 75 lbs, the Bison Bio is priced at $19,950 and aims to drive advancements in healthcare by enabling the creation of complex tissues and organs for biomedical research, supporting personalized medicine and regenerative therapies.
In February 2025, Eli Lilly and Company acquired Organovo’s FXR program, including its lead asset FXR314, for an upfront payment of USD 10 million plus milestone-based payments. The acquisition enables Lilly to leverage Organovo’s 3D-bioprinted human tissue models to generate predictive preclinical data, accelerating FXR314 development and reducing clinical risk. Organovo’s expertise in 3D-bioprinted tissue models supports more efficient drug discovery and testing. This strategic move strengthens Lilly’s pipeline in metabolic and liver-targeted therapies while reflecting a broader industry trend of integrating advanced bioprinting technologies to optimize drug development.
Major companies operating in the 3D bioprinting market are Organovo Holdings Inc., Allevi Inc., Cellink AB, Aspect Biosystems Ltd., Cyfuse Biomedical KK, Poietis SA, TeVido BioDevices, Nano3D Biosciences Inc., RegenHU Ltd., GeSiM mbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, ROKIT Healthcare Co. Ltd., Inventia Life Science Pvt. Ltd., Vivax Bio LLC, 3D Biotek LLC, 3D Bio Corp, 3D Bioprinting Solutions, BICO Group AB, CollPlant Biotechnologies Ltd., 3D Systems Corporation, EnvisionTEC GmbH, GE HealthCare Technologies Inc., Nuclera Nucleics Ltd.
North America was the largest region in the 3D bioprinting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the 3D bioprinting market during the forecast period. The regions covered in the 3D bioprinting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 3D bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the 3D bioprinting market by increasing the cost of imported bioprinters, precision components, and specialized bioink raw materials, disrupting global supply chains and slowing procurement cycles. Research applications, clinical applications, and bioink manufacturing segments are most affected, with regions such as asia-pacific, china, and europe facing higher production and equipment acquisition costs due to their dependence on cross-border technology and material sourcing. Despite these challenges, tariffs are encouraging manufacturers to localize production, strengthen domestic supply chains, and invest in regional bioprinting infrastructure, which is gradually supporting long-term market resilience and innovation.
The 3D bioprinting market research report is one of a series of new reports that provides 3D bioprinting market statistics, including 3D bioprinting industry global market size, regional shares, competitors with a 3D bioprinting market share, detailed 3D bioprinting market segments, market trends and opportunities, and any further data you may need to thrive in the 3D bioprinting industry. This 3D bioprinting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
3D Bioprinting, a form of additive manufacturing, involves the layer-by-layer printing of live structures that emulate the behavior of living systems. This process utilizes cells and biocompatible materials, commonly referred to as bio-inks. The primary application of 3D bioprinting materials is in drug research, and more recently, in the creation of cell scaffolds for repairing damaged ligaments and joints.
The key components in 3D bioprinting include 3D bioprinters and bio-inks. 3D bioprinters employ three-dimensional technology along with biocompatible materials to replicate various body parts, facilitating the bioprinting of tissues, bones, organs, blood vessels, and biomedical components. The materials involved in the process encompass living cells, hydrogels, extracellular matrices, and others. The application of 3D bioprinting extends to research and clinical settings, among others, and finds implementation in diverse sectors such as research organizations, academic institutes, biopharmaceutical companies, hospitals, and more.
The 3D bioprinting market consists of sales of extrusion-based bioprinting, inkjet-based bioprinting, laser-assisted bioprinting, and stereolithography bioprinting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The 3D bioprinting market size is expected to see exponential growth in the next few years. It will grow to $6.21 billion in 2030 at a compound annual growth rate (CAGR) of 23.2%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing organ transplantation demand, regulatory support for bioprinted tissues, growth in biopharmaceutical research pipelines, advancements in scalable bioprinting platforms. Major trends in the forecast period include tissue engineering for regenerative therapies, patient-specific implant fabrication, advanced bioink formulation development, high-resolution multi-material bioprinting, clinical translation of printed tissues.
The anticipated rise in chronic diseases is set to be a driving factor in the prospective growth of the 3D bioprinting market. Chronic diseases, persisting over extended periods - typically three months or more, and often for a person's lifetime - have increasingly utilized 3D bioprinting for creating tissue models, aiding in chronic disease research and potential organ replacement therapies. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, in 2025, over 35 million new cancer cases are predicted, a 77% increase from the estimated 20 million cases in 2022. Consequently, the upsurge in chronic diseases is a significant driver behind the growth of the 3D bioprinting market.
Major companies in the 3D bioprinting market are focusing on developing innovative technological solutions, such as 3D bioprinters, to improve precision and efficiency in tissue engineering and regenerative medicine. 3D bioprinters are devices that utilize bioinks containing living cells to produce three-dimensional tissue and organ structures for medical research and regenerative medicine applications. For example, in June 2024, Tethon 3D, a US-based developer of ceramic powder and metal-polymer products, introduced the Bison Bio DLP 3D bioprinter, marking its entry into the bioprinting market. Developed in collaboration with Carima, this advanced printer offers adjustable build sizes (30 × 20 mm, 57 × 32 mm, and 96 × 54 mm) and is compatible with Tethon’s proprietary LAP photoinitiator and GelMA hydrogel bioink, crucial for bioprinting living tissues. Measuring 24 × 24 × 24 inches and weighing 75 lbs, the Bison Bio is priced at $19,950 and aims to drive advancements in healthcare by enabling the creation of complex tissues and organs for biomedical research, supporting personalized medicine and regenerative therapies.
In February 2025, Eli Lilly and Company acquired Organovo’s FXR program, including its lead asset FXR314, for an upfront payment of USD 10 million plus milestone-based payments. The acquisition enables Lilly to leverage Organovo’s 3D-bioprinted human tissue models to generate predictive preclinical data, accelerating FXR314 development and reducing clinical risk. Organovo’s expertise in 3D-bioprinted tissue models supports more efficient drug discovery and testing. This strategic move strengthens Lilly’s pipeline in metabolic and liver-targeted therapies while reflecting a broader industry trend of integrating advanced bioprinting technologies to optimize drug development.
Major companies operating in the 3D bioprinting market are Organovo Holdings Inc., Allevi Inc., Cellink AB, Aspect Biosystems Ltd., Cyfuse Biomedical KK, Poietis SA, TeVido BioDevices, Nano3D Biosciences Inc., RegenHU Ltd., GeSiM mbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, ROKIT Healthcare Co. Ltd., Inventia Life Science Pvt. Ltd., Vivax Bio LLC, 3D Biotek LLC, 3D Bio Corp, 3D Bioprinting Solutions, BICO Group AB, CollPlant Biotechnologies Ltd., 3D Systems Corporation, EnvisionTEC GmbH, GE HealthCare Technologies Inc., Nuclera Nucleics Ltd.
North America was the largest region in the 3D bioprinting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the 3D bioprinting market during the forecast period. The regions covered in the 3D bioprinting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 3D bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the 3D bioprinting market by increasing the cost of imported bioprinters, precision components, and specialized bioink raw materials, disrupting global supply chains and slowing procurement cycles. Research applications, clinical applications, and bioink manufacturing segments are most affected, with regions such as asia-pacific, china, and europe facing higher production and equipment acquisition costs due to their dependence on cross-border technology and material sourcing. Despite these challenges, tariffs are encouraging manufacturers to localize production, strengthen domestic supply chains, and invest in regional bioprinting infrastructure, which is gradually supporting long-term market resilience and innovation.
The 3D bioprinting market research report is one of a series of new reports that provides 3D bioprinting market statistics, including 3D bioprinting industry global market size, regional shares, competitors with a 3D bioprinting market share, detailed 3D bioprinting market segments, market trends and opportunities, and any further data you may need to thrive in the 3D bioprinting industry. This 3D bioprinting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
3D Bioprinting, a form of additive manufacturing, involves the layer-by-layer printing of live structures that emulate the behavior of living systems. This process utilizes cells and biocompatible materials, commonly referred to as bio-inks. The primary application of 3D bioprinting materials is in drug research, and more recently, in the creation of cell scaffolds for repairing damaged ligaments and joints.
The key components in 3D bioprinting include 3D bioprinters and bio-inks. 3D bioprinters employ three-dimensional technology along with biocompatible materials to replicate various body parts, facilitating the bioprinting of tissues, bones, organs, blood vessels, and biomedical components. The materials involved in the process encompass living cells, hydrogels, extracellular matrices, and others. The application of 3D bioprinting extends to research and clinical settings, among others, and finds implementation in diverse sectors such as research organizations, academic institutes, biopharmaceutical companies, hospitals, and more.
The 3D bioprinting market consists of sales of extrusion-based bioprinting, inkjet-based bioprinting, laser-assisted bioprinting, and stereolithography bioprinting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. 3D Bioprinting Market Characteristics
3. 3D Bioprinting Market Supply Chain Analysis
4. Global 3D Bioprinting Market Trends and Strategies
5. 3D Bioprinting Market Analysis of End Use Industries
7. Global 3D Bioprinting Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global 3D Bioprinting Total Addressable Market (TAM) Analysis for the Market
9. 3D Bioprinting Market Segmentation
10. 3D Bioprinting Market Regional and Country Analysis
11. Asia-Pacific 3D Bioprinting Market
12. China 3D Bioprinting Market
13. India 3D Bioprinting Market
14. Japan 3D Bioprinting Market
15. Australia 3D Bioprinting Market
16. Indonesia 3D Bioprinting Market
17. South Korea 3D Bioprinting Market
18. Taiwan 3D Bioprinting Market
19. South East Asia 3D Bioprinting Market
20. Western Europe 3D Bioprinting Market
21. UK 3D Bioprinting Market
22. Germany 3D Bioprinting Market
23. France 3D Bioprinting Market
24. Italy 3D Bioprinting Market
25. Spain 3D Bioprinting Market
26. Eastern Europe 3D Bioprinting Market
27. Russia 3D Bioprinting Market
28. North America 3D Bioprinting Market
29. USA 3D Bioprinting Market
30. Canada 3D Bioprinting Market
31. South America 3D Bioprinting Market
32. Brazil 3D Bioprinting Market
33. Middle East 3D Bioprinting Market
34. Africa 3D Bioprinting Market
36. 3D Bioprinting Market Competitive Landscape and Company Profiles
37. 3D Bioprinting Market Other Major and Innovative Companies
40. 3D Bioprinting Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
3D Bioprinting Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses 3d bioprinting market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for 3d bioprinting? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The 3d bioprinting market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Component: 3D Bioprinters; Bioinks2) By Material: Living Cells; Hydrogels; Extracellular Matrices; Other Materials
3) By Application: Research Applications; Clinical Application; Other Applications
4) By End User: Research Organization And Academic Institutes; Biopharmaceutical Companies; Hospitals; Other End Users
Subsegments:
1) By 3D Bioprinters: Inkjet 3D Bioprinters; Microextrusion 3D Bioprinters; Laser-Assisted 3D Bioprinters; Stereolithography (SLA) Bioprinters2) By Bioinks: Natural Bioinks; Synthetic Bioinks; Hybrid Bioinks
Companies Mentioned: Organovo Holdings Inc.; Allevi Inc.; Cellink AB; Aspect Biosystems Ltd.; Cyfuse Biomedical KK; Poietis SA; TeVido BioDevices; Nano3D Biosciences Inc.; RegenHU Ltd.; GeSiM mbH; Advanced Solutions Life Sciences LLC; Regenovo Biotechnology Co. Ltd.; Regemat 3D S.L.; Bio3D Technologies; ROKIT Healthcare Co. Ltd.; Inventia Life Science Pvt. Ltd.; Vivax Bio LLC; 3D Biotek LLC; 3D Bio Corp; 3D Bioprinting Solutions; BICO Group AB; CollPlant Biotechnologies Ltd.; 3D Systems Corporation; EnvisionTEC GmbH; GE HealthCare Technologies Inc.; Nuclera Nucleics Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this 3D Bioprinting market report include:- Organovo Holdings Inc.
- Allevi Inc.
- Cellink AB
- Aspect Biosystems Ltd.
- Cyfuse Biomedical KK
- Poietis SA
- TeVido BioDevices
- Nano3D Biosciences Inc.
- RegenHU Ltd.
- GeSiM mbH
- Advanced Solutions Life Sciences LLC
- Regenovo Biotechnology Co. Ltd.
- Regemat 3D S.L.
- Bio3D Technologies
- ROKIT Healthcare Co. Ltd.
- Inventia Life Science Pvt. Ltd.
- Vivax Bio LLC
- 3D Biotek LLC
- 3D Bio Corp
- 3D Bioprinting Solutions
- BICO Group AB
- CollPlant Biotechnologies Ltd.
- 3D Systems Corporation
- EnvisionTEC GmbH
- GE HealthCare Technologies Inc.
- Nuclera Nucleics Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 6.21 Billion |
| Compound Annual Growth Rate | 23.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
